Vanda Pharmaceuticals (VNDA) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $8.07 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- This biotech stock offers a buying opportunity: B. Riley
- Eltek Ltd (ELTK) Reports Q2 EPS of $0.41
- Evogene (EVGN) Tops Q2 EPS by 15c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
